Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Renske Altena is active.

Publication


Featured researches published by Renske Altena.


Lancet Oncology | 2009

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

Renske Altena; P. J. Perik; Dirk J. van Veldhuisen; Elisabeth G.E. de Vries; Jourik A. Gietema

Cardiovascular toxicity is one of the most devastating complications of cancer treatment and can arise during or shortly after treatment, or even several years later. Identification of the left ventricular ejection fraction (LVEF) is the most common method to screen for toxic effects on the heart; however, this approach underestimates cardiac damage and additional strategies for the monitoring of treatment-induced cardiotoxicity are being explored. Guidelines for monitoring have been formulated for several cancer treatments; however, appropriate underlying evidence is still largely absent. In this Review, we summarise conventional and contemporary methods for early detection of cardiotoxicity and designate a level of evidence for the basis of each method.


Annals of Oncology | 2013

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

Joerg Beyer; Peter Albers; Renske Altena; Jorge Aparicio; Carsten Bokemeyer; Jonas Busch; Richard Cathomas; Eva Cavallin-Ståhl; Noel W. Clarke; J Claßen; G. Cohn-Cedermark; Alv A. Dahl; Gedske Daugaard; U. De Giorgi; M. De Santis; M. de Wit; R. de Wit; Klaus Peter Dieckmann; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D. Fosså; J R Germá Lluch; Jourik A. Gietema; Silke Gillessen; A Giwercman; J. T. Hartmann; Axel Heidenreich; Marcus Hentrich; Friedemann Honecker

In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings in 2003 (Essen, Germany) and 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ-cell cancer: a report of the European Germ-Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377–1399; Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478–496; Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer Consensus group (EGCCCG): part II. Eur Urol 2008; 53: 497–513]. A panel of 56 of 60 invited GCC experts from all across Europe discussed all aspects on diagnosis and treatment of GCC, with a particular focus on acute and late toxic effects as well as on survivorship issues. The panel consisted of oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists, who are all actively involved in care of GCC patients. Panelists were chosen based on the publication activity in recent years. Before the meeting, panelists were asked to review the literature published since 2006 in 20 major areas concerning all aspects of diagnosis, treatment and follow-up of GCC patients, and to prepare an updated version of the previous recommendations to be discussed at the conference. In addition, ∼50 E-vote questions were drafted and presented at the conference to address the most controversial areas for a poll of expert opinions. Here, we present the main recommendations and controversies of this meeting. The votes of the panelists are added as online supplements.


JAMA Oncology | 2016

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer : A Randomized Clinical Trial

Annelies H. Boekhout; Jourik A. Gietema; Bojana Milojkovic Kerklaan; Erik van Werkhoven; Renske Altena; Aafke Honkoop; Maartje Los; Willem M. Smit; Peter Nieboer; Carolien H. Smorenburg; Caroline M. Mandigers; Agnes J. van der Wouw; Lonneke Kessels; Annette W. G. van der Velden; P.B. Ottevanger; Tineke J. Smilde; Jaap de Boer; Dirk J. van Veldhuisen; Ido P. Kema; Elisabeth G.E. de Vries; Jan H. M. Schellens

IMPORTANCE This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE To determine as the primary end point whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined as a decline in left ventricular ejection fraction (LVEF) of more than 15% or a decrease below the absolute value 45%. DESIGN This randomized, placebo-controlled clinical study was conducted between October 2007 and October 2011 in 19 hospitals in the Netherlands, enrolling 210 women with early breast cancer testing positive for human epidermal growth factor receptor 2 (HER2) who were being considered for adjuvant systemic treatment with anthracycline-containing chemotherapy followed by trastuzumab. INTERVENTIONS A total of 78 weeks of candesartan (32 mg/d) or placebo treatment; study treatment started at the same day as the first trastuzumab administration and continued until 26 weeks after completion of trastuzumab treatment. MAIN OUTCOMES AND MEASURES The primary outcome was LVEF. Secondary end points included whether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in germline ERBB2 (formerly HER2 or HER2/neu) correlates with trastuzumab-related cardiotoxic effects. RESULTS A total of 206 participants were evaluable (mean age, 49 years; age range, 25-69 years) 103 in the candesartan group (mean age, 50 years; age range, 25-69 years) and 103 in the placebo group (mean age, 50 years; age range, 30-67 years). Of these, 36 manifested at least 1 of the 2 primary cardiac end points. There were 3.8% more cardiac events in the candesartan group than in the placebo group (95% CI, -7% to 15%; P = .58): 20 events (19%) and 16 events (16%), respectively. The 2-year cumulative incidence of cardiac events was 0.28 (95% CI, 0.13-0.40) in the candesartan group and 0.16 (95% CI, 0.08-0.22) in the placebo group (P = .56). Candesartan did not affect changes in NT-proBNP and hs-TnT values, and these biomarkers were not associated with significant changes in LVEF. The Ala1170Pro homozygous ERBB2 genotype was associated with a lower likelihood of the occurrence of a cardiac event compared with Pro/Pro + Ala/Pro genotypes in multivariate analysis (odds ratio, 0.09; 95% CI, 0.02-0.45; P = .003). CONCLUSIONS AND RELEVANCE The findings do not support the hypothesis that concomitant use of candesartan protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer. The ERBB2 germline Ala1170Pro single nucleotide polymorphism may be used to identify patients who are at increased risk of trastuzumab-related cardiotoxic effects. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00459771.


British Journal of Cancer | 2009

Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer

Renske Altena; E. C. de Haas; Janine Nuver; Cornelia Brouwer; M. van den Berg; Andries J. Smit; A. Postma; D.Th. Sleijfer; J. A. Gietema

Long-term cardiovascular morbidity is increasingly observed in chemotherapy-treated testicular cancer survivors, but little is known of early sub-clinical changes in cardiac function. We prospectively evaluated cardiac function in testicular cancer patients by echocardiography. Systolic (Wall Motion Score Index) and diastolic (E/A-ratio and Tissue Velocity Imaging (TVI)) parameters, and serum levels of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) were assessed before the start of chemotherapy and 1 year later. Echocardiography data were compared with an age-matched group of healthy controls. Forty-two patients treated with bleomycin, etoposide and cisplatin were evaluated (median age 27 years, range 18–50). Systolic function and E/A-ratio did not change, whereas the median TVI decreased (12.0 vs 10.0 cms−1; P=0.002). Median levels of NT-proBNP increased (5 vs 18 pmoll−1, P=0.034). Compared with controls, TVI before the start of chemotherapy was not significantly different. In conclusion, we found that at a median of 10 months after cisplatin-based treatment for testicular cancer, TVI decreased significantly, indicating a deterioration of diastolic cardiac function. Serum levels of NT-proBNP increased. The prognostic significance of these changes for future cardiovascular morbidity is not clear.


PLOS ONE | 2015

Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage

Renske Altena; Rudolf Fehrmann; Hink Boer; Elisabeth G.E. de Vries; Coby Meijer; Jourik A. Gietema

Introduction Chemotherapy-related endothelial damage contributes to the early development of cardiovascular morbidity in testicular cancer patients. We aimed to identify relevant mechanisms of and search for candidate biomarkers for this endothelial damage. Methods Human micro-vascular endothelial cells (HMEC-1) were exposed to bleomycin or cisplatin with untreated samples as control. 18k cDNA microarrays were used. Gene expression differences were analysed at single gene level and in gene sets clustered in biological pathways and validated by qRT-PCR. Protein levels of a candidate biomarker were measured in testicular cancer patient plasma before, during and after bleomycin-etoposide-cisplatin chemotherapy, and related to endothelial damage biomarkers (von Willebrand Factor (vWF), high-sensitivity C-Reactive Protein (hsCRP)). Results Microarray data identified several genes with highly differential expression; e.g. Growth Differentiation Factor 15 (GDF-15), Activating Transcription Factor 3 (ATF3) and Amphiregulin (AREG). Pathway analysis revealed strong associations with ‘p53’ and ‘Diabetes Mellitus’ gene sets. Based on known function, we measured GDF-15 protein levels in 41 testicular patients during clinical follow-up. Pre-chemotherapy GDF-15 levels equalled controls. Throughout chemotherapy GDF-15, vWF and hsCRP levels increased, and were correlated at different time-points. Conclusion An unbiased approach in a preclinical model revealed genes related to chemotherapy-induced endothelial damage, like GDF-15. The increases in plasma GDF-15 levels in testicular cancer patients during chemotherapy and its association with vWF and hsCRP suggest that GDF-15 is a potentially useful biomarker related to endothelial damage.


European Journal of Cancer | 2016

Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors

Hink Boer; Nico-Derk L. Westerink; Renske Altena; Janine Nuver; D.A. Janneke Dijck-Brouwer; Martijn van Faassen; Frank Klont; Ido P. Kema; Joop D. Lefrandt; Nynke Zwart; H. Marike Boezen; Andries J. Smit; Coby Meijer; Jourik A. Gietema

PURPOSE Chemotherapy-treated testicular cancer survivors are at risk for development of the metabolic syndrome, especially in case of decreased androgen levels. Polymorphisms in the gene encoding steroid 5-α-reductase type II (SRD5A2) are involved in altered androgen metabolism. We investigated whether single-nucleotide polymorphisms (SNPs) rs523349 (V89L) and rs9282858 (A49T) in SRD5A2 are associated with cardiometabolic status in testicular cancer survivors. METHODS In 173 chemotherapy-treated testicular cancer survivors, hormone levels and cardiometabolic status were evaluated cross-sectionally (median 5 years [range 3-20] after chemotherapy) and correlated with SNPs in SRD5A2. RESULTS The metabolic syndrome was more prevalent in survivors who were homozygous or heterozygous variant for SRD5A2 rs523349 compared to wild type (33% versus 19%, P = 0.032). In particular, patients with lower testosterone levels (<15 nmol/l) and a variant genotype showed a high prevalence of the metabolic syndrome (66.7%). Mean intima-media thickness of the carotid artery and urinary albumin excretion, both markers of vascular damage, were higher in the group of survivors homozygous or heterozygous variant for rs523349 (0.62 versus 0.57 mm, P = 0.026; 5.6 versus 3.1 mg/24 h, P = 0.017, respectively). No association was found between cardiometabolic status and SNP rs9282858 in SRD5A2. CONCLUSION Metabolic syndrome develops more frequently in testicular cancer survivors homozygous or heterozygous variant for SNP rs523349 in SRD5A2. Altered androgen sensitivity appears to be involved in the development of adverse metabolic and vascular changes in testicular cancer survivors and is a target for intervention.


Journal of Clinical Oncology | 2015

Bleomycin-induced pulmonary changes on restaging CT scans

Niek Westerink; Sjoukje Lubberts; den Martine Hollander; Alphons H. H. Bongaerts; Rienhart F. E. Wolf; Renske Altena; Janine Nuver; Sjoukje F. Oosting; de Elisabeth G. E. Vries; Annemiek M.E. Walenkamp; Jacoba Meijer; Jourik A. Gietema


Journal of Clinical Oncology | 2015

Bleomycin-induced pulmonary changes on restaging CT scans : Frequency and correlation with fibrosis markers.

Niek Westerink; Sjoukje Lubberts; Martha W. den Hollander; Alphons H. H. Bongaerts; Rienhart F. E. Wolf; Renske Altena; Janine Nuver; Sjoukje F. Oosting; Elisabeth G.E. de Vries; Annemiek M.E. Walenkamp; Jacoba Meijer; Jourik A. Gietema


Journal of Clinical Oncology | 2015

High risk vascular fingerprint in patients treated with cisplatin-based chemotherapy for testicular cancer

Sjoukje Lubberts; Hink Boer; Renske Altena; Coby Meijer; Arie M. van Roon; Nynke Zwart; Sjoukje F. Oosting; Pieter Willem Kamphuisen; Janine Nuver; Andries J. Smit; André B. Mulder; Joop D. Lefrandt; Jourik A. Gietema


Future Oncology | 2013

Heart matters: cardiovascular complications related to cancer treatment

Renske Altena; Dirk J. van Veldhuisen

Collaboration


Dive into the Renske Altena's collaboration.

Top Co-Authors

Avatar

Jourik A. Gietema

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Elisabeth G.E. de Vries

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Janine Nuver

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Coby Meijer

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Hink Boer

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Sjoukje F. Oosting

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Andries J. Smit

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Dirk J. van Veldhuisen

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Nynke Zwart

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Sjoukje Lubberts

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge